Dr. Cascone on Remaining Challenges With Perioperative Immunotherapy in NSCLC

Partner | Cancer Centers | <b>MD Anderson</b>

Tina Cascone, MD, PhD, discusses remaining challenges with perioperative immunotherapy in non–small cell lung cancer.

Tina Cascone, MD, PhD, assistant professor of thoracic and head and neck cancer, The University of Texas MD Anderson Cancer Center, discusses remaining challenges with perioperative immunotherapy in non—small cell lung cancer (NSCLC).

Single-agent immunotherapy, combinations with immunotherapy plus anti—CTLA-4 agents, or combining immunotherapy with chemotherapy have demonstrated pathologic response benefit for patients with resectable NSCLC.

As such, identifying biomarkers to predict response to therapy and harmonizing treatment options for patients after neoadjuvant chemotherapy remain unmet needs in this space, says Cascone.

Clinical trials measuring overall survival and disease-free survival in response to immunotherapy options and analyses comparing different patient cohorts are in development, concludes Cascone.